

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 6-K**

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of: October 2013

Commission File Number: 001-35776

**Acasti Pharma Inc.**

*(Name of Registrant)*

**545 PROMENADE DU CENTROPOLIS, SUITE 100**

**LAVAL, QUEBEC, CANADA H7T 0A3**

*(Address of Principal Executive Offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☐

Form 40-F ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **Acasti Pharma Inc.**

Date: October 15, 2013

By: /s/ Henri Harland

Name: Henri Harland

Title: Chief Executive Officer

---

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	Interim Financial Statements for the three-month and six-month periods ended August 31, 2013 and 2012
99.2	Management Analysis of the Financial Situation and Operating Results - Three and six-month periods ended August 31, 2013 and 2012
99.3	Certification of Interim Filings - CEO
99.4	Certification of Interim Filings - CFO

Interim Financial Statements of  
(Unaudited)

**ACASTI PHARMA INC.**

Three-month and six-month periods ended August 31, 2013 and 2012

---

**ACASTI PHARMA INC.**

Interim Financial Statements

(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

**Financial Statements**

Interim Statements of Financial Position	1
Interim Statements of Earnings and Comprehensive Loss	2
Interim Statements of Changes in Equity	3
Interim Statements of Cash Flows	4
Notes to Interim Financial Statements	5

---

**ACASTI PHARMA INC.**Interim Statements of Financial Position  
(Unaudited)

As at August 31, 2013 and February 28, 2013

	August 31, 2013	February 28, 2013
<b>Assets</b>		
Current assets:		
Cash	\$ 1,205,627	\$ 1,196,568
Short-term investments	2,759,672	3,588,227
Trade and other receivables	319,205	450,838
Receivable from corporation under common control	49,658	49,658
Tax credits receivable	454,008	335,501
Inventories	67,338	222,125
Prepaid expenses	205,273	16,691
	5,060,781	5,859,608
Equipment	16,457	19,278
Intangible assets (note 5)	20,795,278	6,291,162
<b>Total assets</b>	<b>\$ 25,872,516</b>	<b>\$ 12,170,048</b>
<b>Liabilities and Equity</b>		
Current liabilities:		
Trade and other payables	\$ 1,356,454	\$ 706,883
Payable to parent corporation (note 6)	2,194,363	1,210,604
Royalties payable to parent corporation (notes 5 and 6)	337,051	528,885
<b>Total liabilities</b>	<b>3,887,868</b>	<b>2,446,372</b>
Equity:		
Share capital (note 3)	45,071,939	28,922,710
Warrants and rights (note 3)	406,687	406,687
Contributed surplus	1,753,766	438,711
Deficit	(25,247,744)	(20,044,432)
<b>Total equity</b>	<b>21,984,648</b>	<b>9,723,676</b>
Commitments (note 5)		
<b>Total liabilities and equity</b>	<b>\$ 25,872,516</b>	<b>\$ 12,170,048</b>

See accompanying notes to unaudited interim financial statements.

**ACASTI PHARMA INC.**Interim Statements of Earnings and Comprehensive Loss  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

	Three-month periods ended August 31,		Six-month periods ended August 31,	
	2013	2012	2013	2012
Revenue from sales	\$ 266,151	\$ 237,314	\$ 272,539	\$ 250,972
Cost of sales	(151,307)	(123,739)	(153,209)	(128,299)
Gross profit	114,844	113,575	119,330	122,673
General and administrative expenses	(1,847,874)	(1,094,179)	(3,051,313)	(2,162,807)
Research and development expenses, net of tax credits of \$67,306 and \$118,507 (2012 - \$33,796 and \$107,964)	(1,525,565)	(761,135)	(2,304,192)	(1,320,859)
Results from operating activities	(3,258,595)	(1,741,739)	(5,236,175)	(3,360,993)
Interest income	7,677	15,938	17,899	23,137
Finance costs	(652)	(419)	(1,526)	(1,288)
Foreign exchange gain (loss)	13,366	(26,246)	16,490	10,698
Net finance income (expense)	20,391	(10,727)	32,863	32,547
Net loss and total comprehensive loss for the period	\$ (3,238,204)	\$ (1,752,466)	\$ (5,203,312)	\$ (3,328,446)
Basic and diluted loss per share	\$ (0.04)	\$ (0.02)	\$ (0.07)	\$ (0.05)
Weighted average number of shares outstanding	76,949,761	72,705,133	75,056,632	72,681,730

See accompanying notes to unaudited interim financial statements.

**ACASTI PHARMA INC.**Interim Statements of Changes in Equity  
(Unaudited)

Six-month periods ended August 31, 2013 and 2012

	Share capital		Warrants	Contributed		
	Number	Dollar	and rights	surplus	Deficit	Total
Balance, February 28, 2013	73,107,538	\$28,922,710	\$ 406,687	\$ 438,711	\$(20,044,432)	\$ 9,723,676
Net loss and total comprehensive loss for the period	—	—	—	—	(5,203,312)	(5,203,312)
	73,107,538	28,922,710	406,687	438,711	(25,247,744)	4,520,364
<b>Transactions with owners, recorded directly in equity</b>						
Contributions by and distribution to owners						
Issuance of shares (note 5)	6,750,000	15,496,000	—	—	—	15,496,000
Share-based payment transactions (notes 3 and 4)						
Warrants exercised (note 3)	121,250	30,313	—	1,534,195	—	1,534,195
Share options exercised (note 4)	281,500	622,916	—	(219,140)	—	403,776
Total contributions by and distribution to owners	7,152,750	16,149,229	—	1,315,055	—	17,464,284
Balance at August 31, 2013	80,260,288	\$45,071,939	\$ 406,687	\$ 1,753,766	\$(25,247,744)	\$21,984,648
Balance, February 29, 2012	72,636,888	\$28,614,550	\$ 313,315	\$(1,306,451)	\$(13,152,072)	\$14,469,342
Net loss and total comprehensive loss for the period	—	—	—	—	(3,328,446)	(3,328,446)
	72,636,888	28,614,550	313,315	(1,306,451)	(16,480,518)	11,140,896
<b>Transactions with owners, recorded directly in equity</b>						
Contributions by and distribution to owners						
Share-based payment transactions (notes 3 and 4)						
Warrants exercised (note 3)	103,150	30,848	71,061	981,573	—	1,052,634
Share options exercised (note 4)	20,000	19,540	—	(5,915)	—	25,787
						13,625
Total contributions by and distribution to owners	123,150	50,388	71,061	970,597	—	1,092,046
Balance at August 31, 2012	72,760,038	\$28,664,938	\$ 384,376	\$ (335,854)	\$(16,480,518)	\$12,232,942

See accompanying notes to unaudited interim financial statements.

**ACASTI PHARMA INC.**

 Interim Statements of Cash Flows  
 (Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

	Three-month periods ended August 31,		Six-month periods ended August 31,	
	2013	2012	2013	2012
Cash flows from operating activities:				
Net loss for the period	\$ (3,238,204)	\$ (1,752,466)	\$ (5,203,312)	\$ (3,328,446)
Adjustments:				
Depreciation of equipment	1,338	1,989	2,821	3,960
Amortization of intangible assets	501,182	164,286	665,468	328,572
Stock-based compensation	993,265	523,007	1,534,195	1,052,634
Net finance (income) expense	(20,391)	10,727	(32,863)	(32,547)
Realized foreign exchange gain (loss)	2,607	(7,879)	1,611	7,384
	(1,760,203)	(1,060,336)	(3,032,080)	(1,968,443)
Changes in non-cash operating working capital items:				
Trade and other receivables	284,248	(144,998)	131,633	(258,466)
Tax credits receivable	(67,306)	(33,796)	(118,507)	(107,964)
Inventories	150,166	122,987	154,787	137,348
Prepaid expenses	(162,046)	(6,384)	(188,582)	7,036
Trade and other payables	718,525	1,808	649,571	(169,475)
Payable to parent corporation	559,214	(346,319)	983,759	202,297
Royalties payable to parent corporation	373	86,864	203,234	126,293
	1,483,174	(319,838)	1,815,895	(62,931)
Net cash used in operating activities	(277,029)	(1,380,174)	(1,216,185)	(2,031,374)
Cash flows from investing activities:				
Interest received	56	285	96,454	622
Acquisition of intangible assets	(17,234)	(6,909)	(39,652)	(6,909)
Acquisition of short-term investments	—	—	(3,000,000)	—
Maturity of short-term investments	250,000	1,250,000	3,750,000	1,500,000
Net cash from investing activities	232,822	1,243,376	806,802	1,493,713
Cash flows from financing activities:				
Proceeds from exercise of warrants and options	413,776	26,125	434,089	39,412
Share issue costs	(29,000)	—	(29,000)	—
Interest paid	(652)	(419)	(1,526)	(1,288)
Net cash from financing activities	384,124	25,706	403,563	38,124
Foreign exchange gain (loss) on cash held in foreign currencies	10,759	(18,367)	14,879	3,314
Net increase (decrease) in cash	350,676	(129,459)	9,059	(496,223)
Cash, beginning of period	854,951	1,223,046	1,196,568	1,589,810
Cash, end of period	\$ 1,205,627	\$ 1,093,587	\$ 1,205,627	\$ 1,093,587
Supplemental cash flow disclosure:				
Non-cash transaction:				
Issuance of common shares (note 5)	\$ 15,525,000	\$ —	\$ 15,525,000	\$ —
Royalties settled through issuance of shares (note 5)	395,068	—	395,068	—
Acquisition of intangible asset (note 5)	15,129,932	—	15,129,932	—

See accompanying notes to unaudited interim financial statements.

# ACASTI PHARMA INC.

Notes to Interim Financial Statements  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

---

## 1. Reporting entity

Acasti Pharma Inc. (the "Corporation") is incorporated under the *Business Corporations Act* (Québec) (formerly Part 1A of the *Companies Act* (Québec)). The Corporation is domiciled in Canada and its registered office is located at 545 Promenade du Centropolis, Laval, Québec, H7T 0A3. The Corporation is a majority-owned subsidiary of Neptune Technologies and Bioressources Inc. ("Neptune").

On August 7, 2008, the Corporation commenced operations after having acquired from Neptune an exclusive worldwide license to use its intellectual property to develop, clinically study and market new pharmaceutical products to treat human cardiovascular conditions. Neptune's intellectual property is related to the extraction of particular ingredients from marine biomasses, such as krill. The eventual products are aimed at applications in the over-the-counter medicine, medical foods and prescription drug markets.

Operations essentially consist in the development of new products and the conduct of clinical research studies on animals and humans. Almost all research and development, administration and capital expenditures incurred by the Corporation since the start of the operations are associated with the project described above.

The Corporation is subject to a number of risks associated with the successful development of new products and their marketing, the conduct of its clinical studies and their results, the meeting of development objectives set by Neptune in its license agreement, and the establishment of strategic alliances. The Corporation will have to finance its research and development activities and its clinical studies. To achieve the objectives of its business plan, the Corporation plans to establish strategic alliances, raise the necessary capital and make sales. It is anticipated that the products developed by the Corporation will require approval from the U.S Food and Drug Administration and equivalent organizations in other countries before their sale can be authorized.

## 2. Basis of preparation

### (a) Statement of compliance:

These interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board (IASB), on a basis consistent with those accounting policies followed by the Corporation in the most recent audited annual financial statements, except as disclosed in note 2 (f). These condensed interim financial statements have been prepared under IFRS in accordance with IAS 34, *Interim Financial Reporting*. Certain information, in particular the accompanying notes, normally included in the annual financial statements prepared in accordance with IFRS, have been omitted or condensed. Accordingly the condensed interim financial statements do not include all of the information required for full annual financial statements, and therefore, should be read in conjunction with the audited financial statements and the notes thereto for the year ended February 28, 2013.

### (b) Going concern:

The Corporation has incurred operating losses and negative cash flows from operations since inception. As at August 31, 2013, the Corporation's current liabilities and expected level of expenses in the research and development phase of its drug candidate significantly exceed current assets. The Corporation's liabilities at August 31, 2013 include amounts due to Neptune of \$2,531,414. The Corporation plans to rely on the continued support of Neptune to pursue its operations, including obtaining additional funding, if required. The continuance of this support is outside of the Corporation's control. If the Corporation does not receive the continued financial support from its parent or the Corporation does not raise additional funds, it may not be able to realize its assets and discharge its liabilities in the normal course of business. As a result, there exists a material uncertainty that casts substantial doubt about the Corporation's ability to continue as a going concern and, therefore, realize its assets and discharge its liabilities in the normal course of business.

The financial statements have been prepared on a going concern basis, which assumes the Corporation will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. These financial statements do not include any adjustments to the carrying values and classification of assets and liabilities and reported revenues and expenses that may be necessary if the going concern basis was not appropriate for these financial statements.

### (c) Basis of measurement:

The financial statements have been prepared on the historical cost basis, except for stock-based compensation which is measured in accordance with the provisions of IFRS 2, *Share-Based Payment*.

### (d) Functional and presentation currency:

These financial statements are presented in Canadian dollars, which is the Corporation's functional currency.

## ACASTI PHARMA INC.

Notes to Interim Financial Statements, Continued  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

---

### 2. Basis of preparation (continued):

#### (e) Use of estimates and judgements:

The preparation of the financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates are based on the management's best knowledge of current events and actions that the Corporation may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Critical judgements in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include the following:

- The use of the going concern basis (note 2 (b)).
- Identification of triggering events indicating that intangible assets might be impaired.

Assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year include the following:

- Measurement of stock-based compensation (note 4);
- Allocation of shared costs amongst the Neptune group companies (note 6).

Also, the Corporation uses its best estimate to determine which research and development ("R&D") expenses qualify for R&D tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and therefore, could be different from the amounts recorded.

#### (f) Accounting changes

On March 1, 2013, the Corporation adopted the following new accounting standard issued by the IASB:

- IFRS 13, *Fair Value Measurement* ("IFRS 13"), which defines fair value, sets out in a single IFRS a framework for measuring fair value and requires disclosures about fair value measurements. IFRS 13 does not determine when an asset, a liability or an entity's own equity instrument is measured at fair value. Rather, the measurement and disclosure requirements of IFRS 13 apply when another IFRS requires or permits the item to be measured at fair value (with limited exceptions).

The impact of the adoption of this standard did not have a significant impact on the Corporation's interim financial statements.

### 3. Capital and other components of equity:

#### (a) Share capital:

Authorized capital stock:

Unlimited number of shares:

- Class A shares, voting (one vote per share), participating and without par value.
- Class B shares, voting (ten votes per share), non-participating, without par value and maximum annual non-cumulative dividend of 5% on the amount paid for said shares. Class B shares are convertible, at the holder's discretion, into Class A shares, on a one-for-one basis, and Class B shares are redeemable at the holder's discretion for \$0.80 per share, subject to certain conditions. <sup>1</sup>
- Class C shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of 5%

on the amount paid for said shares. Class C shares are convertible, at the holder's discretion, into Class A shares, on a one-for-one basis, and Class C shares are redeemable at the holder's discretion for \$0.20 per share, subject to certain conditions.<sup>1</sup>

- Class D and E shares, non-voting, non-participating, without par value and maximum monthly non-cumulative dividend between 0.5% and 2% on the amount paid for said shares. Class D and E shares are convertible, at the holder's discretion, into Class A shares, on a one-for-one basis, and Class D and E shares are redeemable at the holder's discretion, subject to certain conditions.<sup>1</sup>

<sup>1</sup> None issued and outstanding

**ACASTI PHARMA INC.**

Notes to Interim Financial Statements, Continued  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

**3. Capital and other components of equity (continued):**

## (b) Warrants:

The warrants of the Corporation are composed of the following as at August 31, 2013 and February 28, 2013:

	August 31, 2013		February 28, 2013	
	Number outstanding	Amount	Number outstanding	Amount
<b>Equity</b>				
Series 4 warrants	5,311,100	\$ —	5,432,350	\$ —
Private placement warrants				
Series 6 warrants	375,000	306,288	375,000	306,288
Series 7 warrants	375,000	100,399	375,000	100,399
	6,061,100	\$ 406,687	6,182,350	\$ 406,687

Series 4 allows the holder to purchase one Class A share for \$0.25 per share until October 8, 2013. During the six-month period ended August 31, 2013, 121,250 warrants (2012: 103,150 warrants) have been exercised for total consideration of \$30,313 (2012: \$25,787).

Series 6 allows the holder to purchase one Class A share for \$1.50 per share until February 10, 2015.

Series 7 allows the holder to purchase one Class A share for \$1.50 per share until February 10, 2015 subject to the achievement of certain agreed upon and predefined milestones. Series 7 warrants are subject to vesting in equal installments over four semesters, subject to continued service and attainment of market (187,500 warrants) and non-market performance conditions (187,500) warrants. The Corporation recognized an expense of nil for this grant during the six-month period ended August 31, 2013 (2012: \$71,016).

**ACASTI PHARMA INC.**

Notes to Interim Financial Statements, Continued  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

**4. Share-based payment:**

Description of the share-based payment arrangements:

At August 31, 2013 the Corporation has the following share-based payment arrangements:

**(a) Corporation stock-based compensation plan:**

The Corporation has established a stock-based compensation plan for directors, officers, employees and consultants. The plan provides for the granting of options to purchase Acasti Class A shares. The exercise price of the stock options granted under this plan is not lower than the closing price of the shares listed on the eve of the grant. Under this plan, the maximum number of options that can be issued equaled 10% of Acasti Class A shares held by public shareholders, as approved annually by such shareholders. On June 27, 2013, the Corporation's shareholders approved the renewal of the Corporation stock option plan, under which the maximum number of options that can be issued is 7,317,128, corresponding to 10% of the shares outstanding as of the date of shareholders' approval. The terms and conditions for acquiring and exercising options are set by the Corporation's Board of Directors, subject, among others, to the following limitations: the term of the options cannot exceed ten years and every stock option granted under the stock option plan will be subject to conditions no less restrictive than a minimal vesting period of 18 months, a gradual and equal acquisition of vesting rights at least on a quarterly basis. The total number of shares issued to a single person cannot exceed 5% of the Corporation's total issued and outstanding shares, with the maximum being 2% for any one consultant.

The number and weighted average exercise prices of share options are as follows:

	Six-month period ended August 31, 2013		Six-month period ended August 31, 2012	
	Weighted average exercise price	Number of options	Weighted average exercise price	Number or options
Outstanding at beginning of period	\$ 1.55	5,216,250	\$ 1.15	3,347,500
Exercised	1.43	(281,500)	0.68	(20,000)
Granted	2.36	140,000	2.10	2,155,000
Forfeited	1.96	(120,000)	—	—
Outstanding at end of period	\$ 1.57	4,954,750	\$ 1.53	5,482,500
Exercisable at end of period	\$ 1.33	3,229,664	\$ 0.95	1,776,333

**ACASTI PHARMA INC.**

Notes to Interim Financial Statements, Continued  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

**4. Share-based payment (continued):****(a) Corporation stock-based compensation plan (continued):**

The fair value of options granted has been estimated according to the Black-Scholes option pricing model and based on the weighted average of the following assumptions for options granted during the six-month periods ended:

	Six-month period ended August 31, 2013	Six-month period ended August 31, 2012
Share price	\$ 2.36	\$ 2.10
Dividend	—	—
Risk-free interest	1.03%	1.34%
Estimated life	2.44 years	4.19 years
Expected volatility	79.42%	70.52%

The weighted average of the fair value of the options granted to employees during the six-month period is \$1.06 (2012 - \$1.13). The weighted average of the fair value of the options granted to non-employees during the six-month period ended August 31, 2012 is \$0.90. No options were granted to non-employees during the six-month period ended August 31, 2013.

The weighted average share price at the date of exercise for options exercised during the six-month period is \$3.84 (2012 - \$2.10).

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation under this plan in the amount of \$279,110 (2012 - \$528,030).

**(b) Corporation equity incentive plan:**

In May 2013, the Board of Directors approved an equity incentive plan for employees, directors and consultants of the Corporation which was subject to the approval of the Toronto Stock Exchange and the shareholders of Acasti. The plan was subsequently approved by the Toronto Stock Exchange and the shareholders' approval was obtained on June 27, 2013. The plan provides for the issuance of restricted share units, performance share units, restricted shares, deferred share units and other share-based awards, under restricted conditions as may be determined by the Board of Directors. Upon fulfillment of the restricted conditions, as the case may be, the plan provides for settlement of the award through shares.

On June 27, 2013, the Corporation granted to board members, executive officers, employees and consultants a total of 1,060,000 Restrictive Share Units (the "APO RSUs") under the Corporation Equity Incentive Plan. APO RSUs will vest gradually overtime with an expiry date of no later than January 15, 2017, based on a specific rate, depending on each holder's category, but sixty percent (60%) of such awards will vest upon achievement of the performance objectives identified by the Corporation.

Performance objectives are based in part on the Corporation's specific and global goals, but also on each holder's individual performance. The fair value of the APO RSUs is determined to be the share price at date of grant and is recognized as stock-based compensation, through contributed surplus, over the vesting period. The fair value of the RSUs granted during the quarter was \$2.89 per unit.

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation under this plan in the amount of \$203,624 (nil in 2012).

**(c) Neptune stock-based compensation plan:**

Neptune maintains various stock-based compensation plans for the benefit of directors, officers, employees, and consultants that provide services to its consolidated group, including the Corporation. The Corporation records as stock-based compensation expense a portion of the expense being recorded by Neptune that is commensurate to the fraction of overall services that the grantees provide directly to the Corporation.

**(i) Neptune stock options:**

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation related to the Neptune plans in the amount of \$394,299 (2012 - \$404,165).

## ACASTI PHARMA INC.

Notes to Interim Financial Statements, Continued  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

---

### 4. Share-based payment (continued):

#### (c) Neptune stock-based compensation plan (continued):

##### (ii) Neptune equity incentive plan:

In January 2013, the Board of Directors approved an equity incentive plan for employees, directors and consultants of Neptune which was subject to the approval of the Toronto Stock Exchange and the shareholders of Neptune. The plan was subsequently approved by the Toronto Stock Exchange and the shareholders' approval was obtained on June 27, 2013. The plan provides for the issuance of restricted share units, performance share units, restricted shares, deferred share units and other share-based awards, under restricted conditions as may be determined by the Board of Directors. Upon fulfillment of the restricted conditions, as the case may be, the plan provides for settlement of the award through shares.

On June 21, 2013, Neptune granted to board members, executive officers, employees and consultants a total of 1,191,000 Restrictive Share Units ("RSUs") under the Neptune equity incentive plan. Neptune RSUs will vest gradually overtime with an expiry date of no later than January 15, 2017, based on a specific rate, depending on each holder's category, but sixty percent (60%) of such awards will vest only upon achievement of the performance objectives identified by Neptune. Performance objectives are based in part on Neptune's specific and global goals, but also on each holder's individual performance.

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation related to this plan in the amount of \$320,623 (nil in 2012).

##### (iii) Neptune-owned NeuroBioPharm Inc. warrants:

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation related to this plan in the amount of \$1,650 (2012 - \$14,267).

##### (iv) Neptune-owned Acasti warrants:

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation related to this plan in the amount of \$1,470 (2012 - \$106,172).

##### (v) Neptune-owned NeuroBioPharm Inc. call-options:

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation related to this plan in the amount of \$486 (nil in 2012).

##### (vi) Neptune-owned Acasti call-options:

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation related to this plan in the amount of \$329,364 (nil in 2012).

#### (d) NeuroBioPharm Inc. Share Bonus plan:

In May 2013, the Board of Directors approved an equity incentive plan for group employees, directors and consultants of NeuroBioPharm Inc. which was subject to the approval of the Toronto Stock Exchange and the shareholders of NeuroBioPharm. The plan was subsequently approved by the Toronto Stock Exchange and the shareholders' approval was obtained on June 27, 2013. The plan provides for the issuance of share bonus awards, under restricted conditions as may be determined by the Board of Directors. Upon fulfillment of the restricted conditions, as the case may be, the plan provides for settlement of the award through shares.

On June 27, 2013, NeuroBioPharm Inc. granted a total of 832,000 Share Bonus Awards under the NeuroBioPharm Share Bonus Plan ("SBAs") to group employees. NeuroBioPharm SBAs will vest gradually overtime with an expiry date of no later than January 15, 2017, based on a specific rate, depending on each holder's category, but sixty percent (60%) of such awards will vest only upon achievement of the performance objectives identified by NeuroBioPharm. Performance objectives are based in part on the NeuroBioPharm's specific and global goals, but also on each holder's individual performance.

For the six-month period ended August 31, 2013, the Corporation recognized stock-based compensation related to this plan in the amount of \$3,569 (nil in 2012).



## ACASTI PHARMA INC.

Notes to Interim Financial Statements, Continued  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

### 5. Commitments:

#### *License agreement:*

The Corporation was initially committed under a license agreement to pay Neptune until the expiration of Neptune's patents on licensed intellectual property, a royalty equal to the sum of (a) in relation to sales of products in the licensed field, if any, the greater of: (i) 7.5% of net sales, and (ii) 15% of the Corporation's gross margin; and (b) 20% of revenues from sub-licenses granted by the Corporation to third parties, if any. The license will expire on the date of expiration of the last-to-expire of the licensed patent claims and/or continuation in part and/or divisional of the licensed patent claims. After the last-to expire of the licensed patents on licensed intellectual property, which is currently expected to occur in 2022, the license will automatically renew for an additional period of 15 years, during which period royalties were to be equal to half of those calculated according to the above formula. In addition, the License Agreement provided for minimum royalty payments notwithstanding the above of: year 1 - nil; year 2 - \$50,000; year 3 - \$200,000; year 4 - \$225,000 (initially \$300,000, but reduced to \$225,000 following Acasti's abandonment of its rights to develop products for the over-the-counter market pursuant to the license); year 5 - \$700,000; and year 6 and thereafter - \$750,000. Minimum royalties are based on contract years based on the effective date of the License Agreement, August 7, 2008.

On December 4, 2012, the Corporation announced that it entered into a Prepayment Agreement with Neptune pursuant to which the Corporation exercised its option under the License Agreement to pay in advance all of the future royalties' payable under the license.

The prepayment and the issuance of the shares to Neptune were approved by the disinterested shareholders of the Corporation at the annual meeting of shareholders of the Corporation held on June 27, 2013 and subsequently by the TSX Venture Exchange.

On July 12, 2013, the Corporation issued 6,750,000 Class A shares, at a price of \$2.30 per share to Neptune.

The transaction was recorded upon the issuance of class A shares. The value of the prepayment, determined with the assistance of outside valuations specialists, using the pre-established formula set forth in the license agreement adjusted to reflect the royalties of \$395,068 accrued from December 4, 2012, date at which the Corporation entered into the prepayment agreement to July 12, 2013, date of issuance of the shares, totalling \$15,129,932, was recognized as an intangible asset. The shares issued as a result of this transaction corresponded to an increase in share capital of \$15,525,000, net of \$29,000 of share issue costs. The Corporation no longer has royalty payment commitment under the License Agreement.

#### *Research and development agreements:*

In the normal course of business, the Corporation has signed agreements with various partners and suppliers for them to execute research projects and to produce and market certain products. The Corporation has reserved certain rights relating to these projects.

The Corporation initiated many research and development projects that will be conducted over a 12 to 24 month period for a total initial cost of \$5,064,000, of which an amount of \$3,447,000 has been paid to date. As at August 31, 2013, an amount of \$531,000 is included in "Trade and other payables" in relation to these projects.

### 6. Related parties:

#### (a) Administrative and research and development expenses:

During the three-month and six-month periods ended August 31, 2013 and 2012, the Corporation was charged by Neptune for certain costs incurred by Neptune for the benefit of the Corporation and for royalties, as follows:

	Three-month period ended August 31, 2013	Three-month period ended August 31, 2012	Six-month period ended August 31, 2013	Six-month period ended August 31, 2012
Administrative costs	\$ 264,717	\$ 294,240	\$ 489,675	\$ 583,593
Research and development costs, before tax credits	179,046	164,650	329,209	352,458
Royalties (note 5)	51,781	75,439	228,219	103,220
	\$ 495,544	\$ 534,329	\$ 1,047,103	\$ 1,039,271

**ACASTI PHARMA INC.**

Notes to Interim Financial Statements, Continued  
(Unaudited)

Three-month and six-month periods ended August 31, 2013 and 2012

**6. Related parties (continued):****(a) Administrative and research and development expenses (continued):**

Where Neptune incurs specific incremental costs for the benefit of the Corporation, it charges those amounts directly. Costs that benefit more than one entity of the Neptune group are being charged by allocating a fraction of costs incurred by Neptune that is commensurate to the estimated fraction of services or benefits received by each entity for those items.

These charges do not represent all charges incurred by Neptune that may have benefited the Corporation, because, amongst others, Neptune does not allocate certain common office expenses and does not charge interest on indebtedness. Also, these charges do not necessarily represent the cost that the Corporation would otherwise need to incur should it not receive these services or benefits through the shared resources of Neptune or receive financing from Neptune.

**(b) Payable to parent corporation:**

Payable to parent corporation has no specified maturity date for payment or reimbursement and does not bear interest.

**(c) Key management personnel compensation:**

The key management personnel of the Corporation are the members of the Board of Directors and certain officers. They control 3% of the voting shares of the Corporation.

Key management personnel compensation includes the following for the three-month and six-month periods ended August 31, 2013 and 2012:

	Three-month period ended August 31, 2013	Three-month period ended August 31, 2012	Six-month period ended August 31, 2013	Six-month period ended August 31, 2012
Short term employee benefits	\$ 158,940	\$ 225,820	\$ 299,107	\$ 451,640
Share based compensation costs	646,311	427,427	1,039,079	864,457
	\$ 805,251	\$ 653,247	\$ 1,338,186	\$ 1,316,097

**7. Operating segments:**

The Corporation has one reportable operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.

The majority of the Corporation's assets are located in Canada.

The Corporation's sales are attributed based on the customer's area of residence. All of the sales were made to the United States.

**8. Subsequent event:**

Since August 31, 2013, 5,311,100 Series 4 warrants have been exercised resulting in the issuance of class A common shares in the same amount. Total proceeds from the exercise amount to \$1,327,775.



## **MANAGEMENT ANALYSIS OF THE FINANCIAL SITUATION AND OPERATING RESULTS – THREE AND SIX-MONTH PERIODS ENDED AUGUST 31, 2013 AND 2012**

### **Introduction**

This management's discussion and analysis ("MD&A") is presented in order to provide the reader with an overview of the financial results and changes to the financial position of Acasti Pharma Inc. ("Acasti" or the "Corporation") as at August 31, 2013 and for the three and six-month periods then ended. This MD&A explains the material variations in the financial statements of operations, financial position and cash flows of Acasti for the three and six-month periods ended August 31, 2013 and 2012. The Corporation effectively commenced active operations with the transfer of an exclusive worldwide license from its parent corporation, Neptune Technologies & Bioresources Inc. ("Neptune"), in August 2008. The Corporation was inactive prior to that date.

This MD&A, completed on October 15, 2013, must be read in conjunction with the Corporation's financial statements for the three and six-month periods ended August 31, 2013 and 2012. The Corporation's financial statements were prepared in accordance with International Financing Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board. The Corporation's financial results are published in Canadian dollars. All amounts appearing in this MD&A are in thousands of Canadian dollars, except share and per share amounts or unless otherwise indicated.

Additional information on the Corporation can be found on the SEDAR website at [www.sedar.com](http://www.sedar.com) and on the EDGAR website at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml) under Acasti Pharma Inc.

On March 31, 2011, following the submission of an initial listing application, the Class A shares of the Corporation were listed for trading on the TSX Venture Exchange under the ticker symbol "APO". In January 2013, the Corporation had its Class A shares listed on the NASDAQ Capital Market exchange, under the symbol "ACST".

### **Forward-Looking Statements**

This MD&A contains certain information that may constitute forward-looking information within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. federal securities laws, both of which Acasti refers to in this MD&A as forward-looking information. Forward-looking information can be identified by the use of terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not statements about the present or historical facts. Forward-looking information in this MD&A includes, but is not limited to, information or statements about:

- Acasti’s ability to conduct current and new clinical trials for its product candidate, including the timing and results of these clinical trials;
- Acasti’s ability to commercialize its products and product candidate;
- Acasti’s ability to secure third-party manufacturer arrangements to provide Acasti with sufficient raw materials for its operations, including, but not limited to, Acasti’s ability to retain a third-party to manufacture CaPre® under good manufacturing practice (“GMP”) standards;
- Acasti’s ability to obtain and maintain regulatory approval of CaPre®; and
- Acasti’s expectations regarding its financial performance, including its revenues, research and development, expenses, gross margins, liquidity, capital resources and capital expenditures.

Although the forward-looking information is based upon what Acasti believes are reasonable assumptions, no person should place undue reliance on such information since actual results may vary materially from the forward-looking information.

In addition, the forward-looking information is subject to a number of known and unknown risks, uncertainties and other factors, including those described in this MD&A under the heading “Risk Factors”, many of which are beyond the Corporation’s control, that could cause the Corporation’s actual results and developments to differ materially from those that are disclosed in or implied by the forward-looking information, including, without limitation:

- whether current and future clinical trials by the Corporation will be successful;
- whether CaPre® and Onemia® can be successfully commercialized;
- the Corporation’s history of net losses and inability to achieve profitability;
- the Corporation’s reliance on third parties for the manufacture, supply and distribution of its products and for the supply of raw materials, including the ability to retain third parties to produce CaPre® under GMP standards;
- the Corporation’s reliance on a limited number of distributors for Onemia® and its ability to secure distribution arrangements for CaPre® if it reaches commercialization;
- the Corporation’s ability to manage future growth effectively;
- the Corporation’s ability to further achieve profitability;
- the Corporation’s ability to secure future financing from Neptune or other third party sources on favorable terms or at all and, accordingly, continue as a going concern;
- the Corporation’s ability to gain acceptance of its products in its markets;
- the Corporation’s ability to attract, hire and retain key management and scientific personnel;
- the Corporation’s ability to achieve its publicly announced milestones on time;
- the Corporation’s ability to successfully defend any product liability lawsuits that may be brought against it;
- intense competition from other companies in the pharmaceutical and medical food industries; and
- the Corporation’s ability to secure and defend its intellectual property rights and to avoid infringing upon the intellectual property rights of third parties.

Consequently, all the forward-looking information is qualified by this cautionary statement and there can be no guarantee that the results or developments that the Corporation anticipates will be realized or, even if substantially realized, that they will have the expected consequences or effects on the Corporation’s business, financial condition or results of operations. Accordingly, you should not place undue reliance on the forward-looking information. Except as required by applicable law, Acasti does not undertake to update or amend any forward-looking information, whether as a result of new information, future events or otherwise. All forward-looking information is made as of the date of this MD&A.

**Business Overview**

Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and polyunsaturated fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are two types of omega-3 fatty acids well known to be beneficial for human health.

CaPre®, currently Acasti's only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. Two Phase II clinical trials were initiated in 2011 in Canada (the TRIFECTA trial and the COLT trial) to evaluate the safety and efficacy of CaPre® for the management of mild to moderate hypertriglyceridemia (high triglycerides with levels ranging from 200 to 500 mg/dl) and severe hypertriglyceridemia (very high triglycerides with levels over 500mg/dl). The results of the COLT trial, for which a final report is being prepared, were disclosed on August 13, 2013 and the TRIFECTA trial is ongoing. Based on the results of the COLT trial, Acasti intends to file an investigational new drug ("IND") submission to conduct a Phase III clinical trial to investigate the safety and efficacy profile of CaPre® in the United States under the guidelines and rules of the U.S. Food and Drug Administration ("FDA").

Onemia® is Acasti's sole commercialized product and has been marketed in the United States since 2011 as a "medical food". Onemia® is only administered under the supervision of a physician and is intended for the dietary management of omega-3 phospholipids deficiency related to abnormal lipid profiles and cardiometabolic disorders.

Pursuant to a license agreement entered into with Neptune in August 2008, Acasti has been granted a license to rights on Neptune's intellectual property portfolio related to cardiovascular pharmaceutical applications (the "License Agreement"). The license allows Acasti to exploit the subject intellectual property rights in order to develop novel active pharmaceutical ingredients ("APIs") into commercial products for the medical food and the prescription drug markets. Acasti is responsible for carrying out the research and development of the APIs, as well as required regulatory submissions and approvals and intellectual property filings relating to the cardiovascular applications. The products developed by Acasti require the approval from the FDA before clinical studies are conducted and approval from similar regulatory organizations before sales are authorized.

**Operations**

During the three-month period ended August 31, 2013, Acasti made progress in its research and pharmaceutical product development, advancing with its prescription drug candidate, CaPre®, while expanding its commercialization efforts for its medical food Onemia®. The following is a summary of the period's highlights.

On December 4, 2012, Acasti reported that it had entered into a prepayment agreement with Neptune pursuant to which Acasti exercised its option under the License Agreement to pay in advance all of the future royalties payable under the License Agreement. The value of the prepayment, determined with the assistance of outside valuations specialists, using the pre-established formula set forth in the License Agreement, and adjusted to reflect the royalties of \$395 accrued from December 4, 2012 to July 12, 2013, amounts to approximately \$15,130, which, pursuant to the prepayment agreement, Acasti agreed to pay through the issuance of 6,750,000 Class A shares, issuable at a price of \$2.30 per share, totalling \$15,525, on July 12, 2013, upon the exercise of a warrant issued to Neptune. The prepayment agreement and the issuance of the 6,750,000 Class A shares to Neptune were approved by the TSX Venture Exchange and the disinterested shareholders of Acasti (excluding Neptune and non-arm's length parties to Neptune) at the annual meeting of shareholders of Acasti held on June 27, 2013. The warrant was exercised by Neptune on July 12, 2013, resulting in the issuance of the 6,750,000 Class A shares. As a result of the royalty prepayment transaction, Acasti is no longer required to pay any royalties to Neptune under the License Agreement during its term for the use of the intellectual property under license. The prepayment increased Neptune's equity participation in Acasti from approximately 57% to approximately 60%.

On July 31, 2013 Acasti announced that it has signed an agreement with a world leader in natural based specialty chemicals for the manufacturing of CaPre® clinical material in expectation of upcoming pharmacokinetics and Phase III clinical trials in the United States and to substantiate its proposed submission of an IND filing.

#### **Clinical Trials Update**

During the fiscal year ended February 29, 2012, Acasti initiated two Phase II clinical trials: (i) the “**TRIFECTA trial**”, a randomized, double-blind, placebo-controlled study primarily designed to assess the effect of CaPre® on fasting plasma triglycerides as compared to a placebo in patients with **mild to severe** hypertriglyceridemia, for which the first patients were enrolled in October 2011, and (ii) the “**COLT trial**”, a randomized open-label dose-ranging, multi-center trial designed to assess the safety and efficacy of CaPre® in the treatment of mild to severe hypertriglyceridemia, for which the first patients were enrolled in December 2011. Acasti’s clinical trials’ recruitment has continued and progressed during the three-month period ended August 31, 2013.

In March 2013, preliminary clinical data from 157 patients enrolled in the COLT trial who have completed four weeks of treatment with 0.5, 1.0, 2.0 or 4.0g of CaPre® per day were assessed and CaPre® achieved a clinically important and statistically significant triglycerides reduction of up to 23% ( $p < 0.05$ ) as compared to the normal standard of care. The COLT trial assesses the effectiveness of CaPre® in patients whose standard of care may be any treatment the treating physicians consider appropriate, ranging from life-style modification to lipid modifying agents such as statins and fibrates. 86% of the patients analyzed in the COLT trial have baseline triglycerides of between 200 and 499mg/dl (2.28 to 5.69 mmol/L) and after the first four weeks no serious adverse events were reported.

On May 22, 2013, the Corporation announced that the recruitment for the COLT trial had been completed.

On August 13, 2013, the Corporation announced positive results for its COLT trial, in which CaPre® was found to be safe and effective with significant mean triglycerides reductions above 20% after 8 weeks of treatment with both daily doses of 4.0g and 2.0g. The study met its primary objective showing CaPre® to be safe and effective in reducing triglycerides in patients with mild to severe hypertriglyceridemia. After only a 4-week treatment, CaPre® achieved a statistically significant triglyceride reduction as compared to Standard of Care. Patients treated with 4.0g of CaPre® a day over 4 weeks reached a mean triglyceride decrease of 15.5% from baseline and an absolute mean improvement of 18.1% as compared to Standard of Care. Results also showed increased benefits after 8 weeks of treatment, with patients on a daily dose of 4.0g of CaPre®, registering a mean triglyceride decrease of 21.6% and an absolute mean improvement of 14.3% as compared to Standard of Care, in which, due to lipid lowering medication adjustment, a significant improvement in triglyceride levels was observed during the trial between 4 weeks and 8 weeks. No serious adverse events were reported, indicating that CaPre® is safe and tolerable at all doses tested. Furthermore, data revealed a positive risk/benefit ratio for CaPre®, with patients on CaPre® showing a lower incidence of adverse events compared to the Standard of Care group. In addition, after doubling the daily dosage of CaPre® from 4 to 8 weeks, the results indicate a dose response relationship revealing a maintained and improved efficacy of CaPre® after an 8-week period. The efficacy of CaPre® at all doses and increased effect with dose escalation suggests that CaPre® may be titratable, allowing physicians to adjust dosage in order to better manage patients’ medical needs.

#### **Onemia®**

During the three-month period ended August 31, 2013, Acasti furthered its business development and direct commercialization activities in the U.S. for its medical food Onemia®. Physicians initiated and/or continued their recommendations of Onemia® for patients diagnosed with cardiometabolic disorders. Acasti expects continued sales of Onemia® to provide short-term revenues that will contribute, in part, to finance Acasti’s research and development projects while establishing Acasti’s omega-3 phospholipids product credentials.

#### **Basis of presentation of the financial statements**

The Corporation’s assets as at August 31, 2013 include cash and short-term investments for an amount of \$3,965, mainly generated by the exercise on September 14, 2011 of the rights issued by the Corporation to its shareholders, by the net proceeds from a \$1,979 private financing completed on February 13, 2012 as well as proceeds from sales of Onemia®. The

Corporation also has trade and other receivables of \$319, receivable from a corporation under common control of \$50, tax credits receivable for an amount of \$454 and prepaid expenses of \$205 as at August 31, 2013. The Corporation's liabilities at August 31, 2013 are comprised primarily of amounts due to Neptune of \$2,194 and other creditors for \$1,356 as well as royalties payable to Neptune for \$337, accrued prior to entering into the prepayment agreement. The Corporation has incurred operating losses and negative cash flows from operations since inception. As at August 31, 2013, the Corporation's current liabilities and expected level of expenses in the research and development phase of its drug candidate significantly exceed current assets. The Corporation plans to rely on the continued support of Neptune to pursue its operations, including obtaining additional funding, if required. The continuance of this support is outside of the Corporation's control. If the Corporation does not receive the continued financial support from its parent or the Corporation does not raise additional funds, it may not be able to realize its assets and discharge its liabilities in the normal course of business. As a result, there exists a material uncertainty that casts substantial doubt about the Corporation's ability to continue as a going concern and, therefore, realize its assets and discharge its liabilities in the normal course of business.

The financial statements have been prepared on a going concern basis, which assumes the Corporation will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. These financial statements do not include any adjustments to the carrying values and classification of assets and liabilities and reported revenues and expenses that may be necessary if the going concern basis was not appropriate for these financial statements.

The Corporation is subject to a number of risks associated with the successful development of new products and their marketing, the conduct of its clinical studies and their results, the meeting of development objectives set by Neptune in its License Agreement, and the establishment of strategic alliances. The Corporation will have to finance its research and development activities and its clinical studies. To achieve the objectives of its business plan, the Corporation plans to establish strategic alliances, raise the necessary capital and make sales. It is anticipated that the products developed by the Corporation will require approval from the FDA and equivalent organizations in other countries before their sale can be authorized.

## SELECTED FINANCIAL INFORMATION

(In thousands of dollars, except per share data)

	Three-month periods ended		Six-month periods ended	
	August 31, 2013	August 31, 2012	August 31, 2013	August 31, 2012
	\$	\$	\$	\$
Revenue from sales	266	237	273	251
Adjusted EBITDA <sup>(1)</sup>	(1,755)	(1,037)	(3,015)	(1,953)
Net loss and comprehensive loss	(3,238)	(1,752)	(5,203)	(3,328)
Net loss per share and diluted loss per share	(0.04)	(0.02)	(0.07)	(0.05)
Total assets	25,873	13,652	25,873	13,652
Working capital <sup>(2)</sup>	1,173	5,686	1,173	5,686
Total equity	21,985	12,233	21,985	12,233
Book value per Class A share <sup>(3)</sup>	0.27	0.17	0.27	0.17

(1) The Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is presented for information purposes only and represents a financial performance measurement tool mostly used in financial circles. Because there is no standard method endorsed by IFRS requirements, the results are unlikely to be comparable to similar measurements presented by other public companies. Acasti obtains Adjusted EBITDA measurement by adding to net loss finance costs, depreciation and amortization and income taxes. Acasti also excludes the effects of certain non-monetary transactions recorded, such as gain or loss on foreign exchange and stock-based compensation, for its Adjusted EBITDA calculation.

(2) The working capital is presented for information purposes only and represents a measurement of the Corporation's short-term financial health mostly used in financial circles. The working capital is calculated by subtracting current liabilities from current assets. Because there is no standard method endorsed by IFRS requirements, the results may not be comparable to similar measurements presented by other public companies.

(3) The book value per share is presented for information purposes only and is obtained by dividing the shareholders' equity by the number of outstanding Class A shares at the end of the period. Because there is no standard method endorsed by IFRS requirements, the results may not be comparable to similar measurements presented by other public companies.

**RECONCILIATION OF THE EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION (ADJUSTED EBITDA)**

A reconciliation of Adjusted EBITDA is presented in the table below. The Corporation uses adjusted financial measures to assess its operating performance. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Corporation uses Adjusted EBITDA to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our operating performance, and because the Corporation believes it provides meaningful information on the Corporation financial condition and operating results.

Acasti obtains its Adjusted EBITDA measurement by adding to net loss, finance costs, depreciation and amortization and income taxes. Acasti also excludes the effects of certain non-monetary transactions recorded, such as gain or loss on foreign exchange and stock-based compensation, from its Adjusted EBITDA calculation. The Corporation believes it is useful to exclude these items as they are either non-cash expenses, items that cannot be influenced by management in the short term, or items that do not impact core operating performance. Excluding these items does not imply they are necessarily nonrecurring.

**RECONCILIATION OF ADJUSTED EBITDA**

(In thousands of dollars, except per share data)

	Three-month periods ended		Six-month periods ended	
	August 31, 2013	August 31, 2012	August 31, 2013	August 31, 2012
	\$	\$	\$	\$
Net loss	(3,238)	(1,752)	(5,203)	(3,328)
<b>Add (deduct)</b>				
Finance costs	1	-	2	1
Depreciation and amortization	502	166	668	332
Stock-based compensation	993	523	1,534	1,053
Foreign exchange (gain) loss	(13)	26	(16)	(11)
Adjusted EBITDA	(1,755)	(1,037)	(3,015)	(1,953)

**SELECTED QUARTERLY FINANCIAL DATA**

(In thousands of dollars, except per share data)

**Fiscal year ended February 28, 2014**

	Total	First	Second	Third	Fourth
	\$	Quarter	Quarter	Quarter	Quarter
	\$	\$	\$	\$	\$
Revenue from sales	273	6	266		
Adjusted EBITDA <sup>(1)</sup>	(3,015)	(1,260)	(1,755)		
Net loss	(5,203)	(1,965)	(3,238)		
Loss per share basic and diluted	(0.07)	(0.03)	(0.04)		

**Fiscal year ended February 28, 2013**

	Total	First	Second	Third	Fourth
	\$	Quarter	Quarter	Quarter	Quarter
	\$	\$	\$	\$	\$
Revenue from sales	724	14	237	424	49
Adjusted EBITDA <sup>(1)</sup>	(4,350)	(916)	(1,037)	(1,036)	(1,361)
Net loss	(6,892)	(1,576)	(1,752)	(1,611)	(1,953)
Loss per share basic and diluted	(0.09)	(0.02)	(0.02)	(0.02)	(0.03)

**Fiscal year ended February 29, 2012**

	Total	First	Second	Third	Fourth
	\$	Quarter	Quarter	Quarter	Quarter
	\$	\$	\$	\$	\$
Revenue from sales	10	–	–	–	10
Other Income - Revenue from research contracts	116	83	33	–	–
Adjusted EBITDA <sup>(1)</sup>	(4,481)	(693)	(1,254)	(1,677)	(857)
Net loss	(6,501)	(1,023)	(1,724)	(2,207)	(1,547)
Loss per share basic and diluted	(0.10)	(0.02)	(0.03)	(0.03)	(0.02)

- (1) The Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is presented for information purposes only and represents a financial performance measurement tool mostly used in financial circles. Because there is no standard method endorsed by IFRS requirements, the results are unlikely to be comparable to similar measurements presented by other public companies. Acasti obtains Adjusted EBITDA measurement by adding to net loss, finance costs, depreciation and amortization and income taxes. Acasti also excludes the effects of certain non-monetary transactions recorded, such as gain or loss on foreign exchange and stock-based compensation, for its Adjusted EBITDA calculation.

**COMMENTS ON THE SIGNIFICANT VARIATIONS OF RESULTS FROM OPERATIONS FOR THE THREE AND SIX-MONTH PERIODS ENDED AUGUST 31, 2013 AND 2012****Revenues**

The Corporation generated revenues from sales of \$266 from the commercialization of Onemia®, its medical food product, during the three-month period ended August 31, 2013. The revenues were generated from a distribution agreement the Corporation entered into with a US distributor specialized in medical food, as well as from sales made directly to customers in the United States. The Corporation generated revenue from sales of \$237 during the corresponding period in 2012.

The Corporation generated revenues from sales of \$273 from the commercialization of Onemia®, its medical food product, during the six-month period ended August 31, 2013, an increase of \$22 from the revenues of \$251 generated during corresponding period of 2012.

**Gross Profit**

Gross profit is calculated by deducting the cost of sales from revenue. Cost of sales consists primarily of costs incurred to manufacture products. It also includes related overheads, such as certain costs related to quality control and quality assurance, inventory management, sub-contractors and costs for servicing and commissioning.

The gross profit for the three-month period ended August 31, 2013 amounted to \$115 or 43%, which is the Corporation's adjusted target range for its gross profit margin, being 40 to 60%. The Corporation decided to adjust, earlier this quarter, its target range for its profit margin due to the early nature of its commercialization activities. The Corporation realized a gross profit of \$114 or 48% during the three-month period ended August 31, 2012.

The gross profit for the six-month period ended August 31, 2013 amounted to \$119 or 44%, which is in the Corporation's adjusted target range for its gross profit margin. The Corporation realized a gross profit of \$123 or 49% during the six-month period ended August 31, 2012.

**Breakdown of Major Components of the Statement of Earnings and Comprehensive Loss for the three and six-month periods ended August 31, 2013 and 2012**

General and administrative expenses	Three-month periods ended August 31,		Six-month periods ended August 31,	
	2013	2012	2013	2012
	\$	\$	\$	\$
Salaries and benefits	237	243	443	512
Stock-based compensation	875	416	1,290	835
Professional fees	102	118	271	215
Royalties	52	75	228	103
Amortization and depreciation	502	166	668	332
Sales and marketing	3	39	9	94
Investor relations	29	12	55	22
Rent	23	12	51	18
Other	25	13	36	32
<b>TOTAL</b>	<b>1,848</b>	<b>1,094</b>	<b>3,051</b>	<b>2,163</b>

Research and development expenses	Three-month periods ended August 31,		Six-month periods ended August 31,	
	2013	2012	2013	2012
	\$	\$	\$	\$
Salaries and benefits	145	167	301	357
Stock-based compensation	118	107	244	218
Contracts	1,211	477	1,675	696
Regulatory expenses	-	8	1	70
Professional fees	95	22	151	49
Other	23	14	52	39
Tax credits	(67)	(34)	(119)	(108)
<b>TOTAL</b>	<b>1,526</b>	<b>761</b>	<b>2,304</b>	<b>1,321</b>

**Adjusted Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)**

Adjusted EBITDA decreased by \$718 for the three-month period ended August 31, 2013 to \$(1,755) compared to \$(1,037) for the three-month period ended August 31, 2012, mainly due to the increase in research and development expenses before consideration of stock-based compensation and amortization and depreciation.

The increase in research and development expenses is mainly attributable to increases in contract expenses related to the Corporation's clinical trials and professional fees.

Adjusted EBITDA decreased by \$1,062 for the six-month period ended August 31, 2013 to \$(3,015) compared to \$(1,953) for the six-month period ended August 31, 2012, mainly due to the increase in research and development expenses before consideration of stock-based compensation and amortization and depreciation.

The increase in research and development expenses is mainly attributable to increases in contract expenses related to the Corporation's clinical trials and professional fees.

### **Net Loss**

The Corporation realized a net loss for the three-month period ended August 31, 2013 of \$3,238 or \$0.04 per share compared to a net loss of \$1,752 or \$0.02 per share for the three-month period ended August 31, 2012. These results are mainly attributable to the factors described above in the Gross Profit and Adjusted EBITDA sections as well as by increases in amortization and depreciation and stock based compensation expenses.

The Corporation realized a net loss for the six-month period ended August 31, 2013 of \$5,203 or \$0.07 per share compared to a net loss of \$3,328 or \$0.05 per share for the six-month period ended August 31, 2012. These results are mainly attributable to the factors described above in the Gross Profit and Adjusted EBITDA sections as well as by increases in amortization and depreciation and stock based compensation expenses.

### **Share Capital Structure**

The authorized share capital consists of an unlimited number of Class A, Class B, Class C, Class D and Class E shares, without par value. Issued and outstanding fully paid shares, outstanding warrants and outstanding stock options were as follows:

	August 31, 2013	February 28, 2013
Class A shares, voting, participating and without par value	80,260,288	73,107,538
Stock options granted and outstanding	4,954,750	5,216,250
Restricted Shares Units granted and outstanding	1,060,000	-
Series 4 warrants exercisable at \$0.25 until October 8, 2013	5,311,100	5,432,350
Series 6 & 7 warrants exercisable at \$1.50 until February 10, 2015	750,000	750,000
Total fully diluted shares	91,276,138	84,506,138

### **Cash Flows and Financial Condition between the Three and six-month periods ended August 31, 2013 and 2012**

#### **Operating activities**

During the three-month periods ended August 31, 2013 and 2012, the Corporation's operating activities generated decreases in liquidity of \$277 and \$1,380, respectively, consisting of the net loss incurred for the quarter adjusted for non-cash items, such as depreciation of equipment, amortization of intangible asset, stock-based compensation, finance expenses and foreign exchange, as well as for the net changes in non-cash operating working capital items for the period. The net changes in non-cash operating working capital items for the three-month period ended August 31, 2013 amounted to an increase of \$1,483 and is mainly due to decreases in trade and other receivables (\$284), inventories (\$150) as well as increases in trade and other payables (\$718) and payable to parent corporation (\$559), principally offset by the increase in prepaid expenses (\$162). The net changes in non-cash operating working capital items for the three-month period ended August 31, 2012, amounted to a decrease of \$320 and is mainly due to increases in trade and other receivables (\$145) and tax credit receivables (\$34) as well as the decrease in payable to parent corporation (\$346), principally offset by the decrease in inventories (\$123), as well as the increase in royalties payable to the parent corporation (\$87).

During the six-month periods ended August 31, 2013 and 2012, the Corporation's operating activities generated decreases in liquidity of \$1,216 and \$2,031, respectively, consisting of the net loss incurred for the quarter adjusted for non-cash items, such as depreciation of equipment, amortization of intangible asset, stock-based compensation, finance expenses

and foreign exchange, as well as for the net changes in non-cash operating working capital items for the period. The net changes in non-cash operating working capital items for the six-month period ended August 31, 2013 amounted to an increase of \$1,816 and is mainly due to decreases in trade and other receivables (\$132), inventories (\$155) as well as increases in trade and other payables (\$650), payable to parent corporation (\$984) and royalties payable to parent corporation (\$203), principally offset by increases in tax credits receivables (\$119) and prepaid expenses (\$189). The net changes in non-cash operating working capital items for the six-month period ended August 31, 2012, amounted to a decrease of \$63 and is mainly due to increases in trade and other receivables (\$258) and tax credit receivables (\$108) as well as decreases in trade and other payables (\$169), principally offset by the decrease in inventories (\$137), as well as increases in payable to parent corporation (\$202) and royalties payable to the parent corporation (\$126).

**Investing activities**

During the three-month periods ended August 31, 2013 and 2012, the Corporation's investing activities generated increases in liquidities of \$233 and \$1,243, respectively. The increase in liquidity generated by investing activities during the three-month period ended August 31, 2013 is mainly due to the maturity of short-term investments of \$250, offset by the acquisition of intangible assets of \$17. The increase in liquidity generated by investing activities during the three-month period ended August 31, 2012 is mainly due to the maturity of short-term investment of \$1,250, offset by the acquisition of intangible assets of \$7.

During the six-month periods ended August 31, 2013 and 2012, the Corporation's investing activities generated increases in liquidities of \$807 and \$1,494, respectively. The increase in liquidity generated by investing activities during the six-month period ended August 31, 2013 is mainly due to the maturity of short-term investments of \$3,750 and the interest received on short-term investments of \$96, offset by acquisitions of short term investments of \$3,000 and intangible assets of \$40. The increase in liquidity generated by investing activities during the six-month period ended August 31, 2012 is mainly due to the maturity of short-term investment of \$1,500, offset by the acquisition of intangible assets of \$7.

**Financing activities**

During the three-month periods ended August 31, 2013 and 2012, the Corporation's financing activities generated increases in liquidities of \$384 and \$26, respectively. The increase in liquidities generated from financing activity during the three-month periods ended August 31, 2013 resulted mainly from proceeds from exercise of warrants and options of \$414, principally offset by share issue costs of \$29. The increase in liquidities generated from financing activity during the three-month periods ended August 31, 2012 resulted mainly from proceeds from exercise of warrants and options of \$26.

During the six-month periods ended August 31, 2013 and 2012, the Corporation's financing activities generated increases in liquidities of \$404 and \$38, respectively. The increase in liquidities generated from financing activity during the six-month periods ended August 31, 2013 resulted mainly from proceeds from exercise of warrants and options of \$434, principally offset by share issue costs of \$29. The increase in liquidities generated from financing activity during the six-month periods ended August 31, 2012 resulted mainly from proceeds from exercise of warrants and options of \$39.

Overall, as a result, the Corporation's cash increased by \$351 and decreased by \$129, respectively, for the three-month periods ended August 31, 2013 and 2012. Total liquidities as at August 31, 2013, comprised of cash and short-term investments, amounted to \$3,965. See basis of presentation for additional discussion of the Corporation's financial condition.

To date, the Corporation has financed its operations primarily through the exercise of rights and warrants issued to its shareholders as well as to Neptune and its shareholders, the private offerings of shares, as well as research tax credits, revenues from sales and research contracts, as well as interest income. The future profitability of the Corporation is dependent upon such factors as the success of the clinical trials, the approval by regulatory authorities of products developed by the Corporation, the ability of the Corporation to successfully market, sell and distribute products, and the ability of the Corporation to obtain the necessary financing to complete its projects.

**Financial Position**

The following table details the significant changes to the statements of financial position as at August 31, 2013 compared to February 28, 2013:

Accounts	Increase (Decrease)	Comments
Cash	9	See cash flow statement
Short-term investments		Maturity of short-term investments to finance operations
	(829)	
Trade and other receivables	(132)	Amounts received
Tax credits receivable	119	Increase in tax credit eligible expenses
Inventories	(155)	Onemia® sales
Prepaid expenses	189	Increases in advance payments
Intangible assets	14,504	Acquisition of royalty free license
Trade and other payables	650	Increase in amount owed related to research contracts
Payable to parent corporation	984	Charges for Corporation's expenses
Royalties payable to parent corporation	(191)	Adjustment for royalty prepayment

**Contractual Obligations, Off-Balance-Sheet Arrangements and Commitments**

The Corporation has no off-balance sheet arrangements. All of the Corporation's liabilities (\$3,889) are due within twelve months.

Significant commitments include:

**License Agreement**

The Corporation was initially committed under the License Agreement to pay Neptune until the expiration of Neptune's patents on licensed intellectual property a royalty equal to the sum of (a) in relation to sales of products in the licensed field, if any, the greater of: (i) 7.5% of net sales, and (ii) 15% of Acasti's gross margin; and (b) 20% of revenues from sub-licenses granted by Acasti to third parties, if any. The license will expire on the date of expiration of the last-to-expire of the licensed patent claims and/or continuation in part and/or divisional of the licensed patent claims. After the last-to expire of the licensed patents on licensed intellectual property, which is currently expected to occur in 2022, the license will automatically renew for an additional period of 15 years, during which period royalties were to be equal to half of those calculated according to the above formula. In addition, the License Agreement provided for minimum royalty payments notwithstanding the above of: year 1 - nil; year 2 - \$50; year 3 - \$200; year 4 - \$225 (initially \$300, but reduced to \$225 following Acasti's abandonment of its rights to develop products for the over-the-counter market pursuant to the license); year 5 - \$700; and year 6 and thereafter - \$750. Minimum royalties are based on contract years based on the effective date of the License Agreement, August 7, 2008.

On December 4, 2012, the Corporation announced that it entered into a prepayment agreement with Neptune pursuant to which the Corporation exercised its option under the License Agreement to pay in advance all of the future royalties' payable under the license. The value of the prepayment, determined with the assistance of outside valuations specialists, using the pre-established formula set forth in the License Agreement, and adjusted to reflect the royalties of \$395 accrued from December 4, 2012 to July 12, 2013, amounts to approximately \$15,130. The prepayment and accrued royalties have been paid through the issuance of 6,750,000 Class A shares of Acasti, issued at a price of \$2.30 per share, totalling \$15,525, on July 12, 2013, upon the exercise of a warrant delivered to Neptune at the signature of the prepayment agreement and following the Corporation's disinterested shareholders and TSX Venture Exchange approvals. The Corporation no longer has royalty payment commitment under the License Agreement.

### **Research and development agreements**

In the normal course of business, the Corporation has signed agreements with various partners and suppliers for them to execute research projects and to produce and market certain products.

The Corporation initiated research and development projects that will be conducted over a 12 to 24 month period for a total initial cost of \$5,064, of which an amount of \$3,447 has been paid to date. As at August 31, 2013, an amount of \$531 is included in "Trade and other payables" in relation to these projects.

### **Related Party Transactions**

The Corporation was charged by Neptune for certain costs incurred by Neptune for the benefit of the Corporation in the amount of \$496 during the three-month period ended August 31, 2013 (\$265 for administrative costs, \$179 for research and development costs and \$52 for royalties for the period prior to the royalty prepayment transaction being effective) and \$534 during the three-month period ended August 31, 2012 (\$294 for administrative costs, \$165 for research and development costs and \$75 for royalties). These transactions are in the normal course of operations. Where Neptune incurs specific incremental costs for the benefit of the Corporation, it charges those amounts directly. Costs that benefit more than one entity of the Neptune group are being charged by allocating a fraction of costs incurred by Neptune that is commensurate to the estimated fraction of services or benefits received by each entity for those items. These charges do not represent all charges incurred by Neptune that may have benefited the Corporation, because, amongst others, Neptune does not allocate certain common office expenses and does not charge interest on indebtedness. Also, these charges do not necessarily represent the cost that the Corporation would otherwise need to incur should it not receive these services or benefits through the shared resources of Neptune or receive financing from Neptune.

Payable to parent corporation has no specified maturity date for payment or reimbursement and does not bear interest. This amount has been measured at the exchange amount and classified as current liabilities.

The key management personnel of the Corporation are the members of the Board of Directors and certain officers. They control 3% of the voting shares of the Corporation. See note 6 to the financial statements for disclosures of key management personnel compensation.

On December 4, 2012, the Corporation entered into a prepayment agreement with Neptune as detailed under "Contractual Obligations, Off-Balance Sheet Arrangements and Commitments – License Agreement".

### **Subsequent events**

Since the end of the quarter, 5,311,100 Series 4 warrants have been exercised into Class A shares, representing total proceeds of \$1,328, of the number of Series 4 warrants exercised, 3,153,750 warrants have been exercised by Neptune, increasing its current holding of Class A shares from 48,175,933 (58%) to 51,329,683 (60%).

### **Use of estimates and measurement of uncertainty**

The preparation of the financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates are based on the management's best knowledge of current events and actions that the Corporation may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include the use of the going concern basis (See note 2 (b) of the financial statements) and the identification of triggering events indicating that intangible assets might be impaired. Assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year include allocation of shared costs amongst the Neptune group companies (note 6 to financial statements) and

the measurement of stock-based compensation (note 4 to the financial statements). Also, the Corporation uses its best estimate to determine which research and development (“R&D”) expenses qualify for R&D tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and therefore, could be different from the amounts recorded.

### **Critical Accounting Policies**

#### **Research and development expenses**

Research expenses are charged to income in the period of expenditure less related tax credits. Development costs are charged to income as incurred unless a development project meets generally accepted accounting criteria for deferral and amortization. The Corporation has not deferred any development costs since inception.

#### **Tax credits**

Tax credits related to eligible expenses are accounted for as a reduction of related costs in the year during which the expenses are incurred as long as there is reasonable assurance of their realization.

#### **Stock-based compensation**

The Corporation has a stock-based compensation plan, which is described in note 4 of the financial statements. The Corporation accounts for stock options granted to employees based on the fair value method, with fair value determined using the Black-Scholes model. Under the fair value method, compensation cost is measured at fair value at date of grant and is expensed over the award’s vesting period with a corresponding increase in contributed surplus. For stock options granted to non-employees, the Corporation measures based on the fair value of services received, unless those are not reliably estimable, in which case the Corporation measures the fair value of the equity instruments granted. Compensation cost is measured when the company obtains the goods or the counterparty renders the service.

Also, the Corporation records as stock-based compensation expense a portion of the expense being recorded by Neptune that is commensurate to the fraction of overall services that the grantees provide directly to the Corporation with the offset to contributed surplus reflecting Neptune’s contribution to the Corporation.

#### **Income taxes**

The Corporation follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are determined based on the differences between the carrying value and tax bases of assets and liabilities and they are measured using substantively enacted tax rates and laws that are expected during the periods when the temporary differences are expected to be realized or settled. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. The Corporation has not recognized any deferred tax assets in its financial statements because it has determined that they are not probable of being realized.

### **Recently Adopted Accounting Policies**

On March 1, 2013, the Corporation adopted the following new accounting standard issued by the IASB: IFRS 13, Fair Value Measurement (“IFRS 13”), which defines fair value, sets out in a single IFRS a framework for measuring fair value and requires disclosures about fair value measurements. IFRS 13 does not determine when an asset, a liability or an entity’s own equity instrument is measured at fair value. Rather, the measurement and disclosure requirements of IFRS 13 apply when another IFRS requires or permits the item to be measured at fair value (with limited exceptions). The impact of the adoption of this standard did not have a significant impact on the Corporation’s interim financial statements.

### **Changes in Internal Control over Financial Reporting**

During the three-month period ended August 31, 2013, the Chief Executive Officer and the Chief Financial Officer of the Corporation evaluated whether there were any material changes in internal control over financial reporting pursuant to National Instrument 52-109 – Certification of Disclosure in Issuers’ Annual and Interim Filings. They individually concluded that there were no changes during the three-month period ended August 31, 2013 that affected materially or is reasonably likely to affect materially the Corporation’s internal controls over financial reporting.

### **Risk Factors**

Investing in securities of the Corporation involves a high degree of risk. The information contained in the financial statements for the three and six-month periods ended August 31, 2013 and 2012 and this MD&A should be read in conjunction with all of the Corporation and Neptune’s public filings with securities regulatory authorities. In particular, prospective investors should carefully consider the risks and uncertainties described in our filings with securities regulators, including those described under the heading “Risk Factors” in our listing application and in our latest annual information form, which are available on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml).

Additional risks and uncertainties, including those of which the Corporation is currently unaware or that it deems immaterial, may also adversely affect the Corporation’s business, financial condition, liquidity, results of operation and prospects.

### **Product Liability**

The parent corporation Neptune has secured a \$5,000 product liability insurance policy, which also covers its subsidiaries, renewable on an annual basis, to cover civil liability relating to its products. Neptune also maintains a quality-assurance process that is “Quality Management Program” certified by the Canadian Food Inspection Agency and has obtained GMP accreditation from Health Canada.

### **Additional Information**

Updated and additional information on the Corporation and the parent corporation Neptune Technologies & Bioresources is available from the SEDAR Website at [www.sedar.com](http://www.sedar.com) or on EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml).

As at October 15, 2013, the total number of Class A shares of the Corporation issued and outstanding was 85,571,388. The Corporation also has 4,899,750 stock options, 1,035,000 restricted shares units and 750,000 Series 6 & 7 warrants outstanding.

*/s/ Henri Harland*

Henri Harland  
President & Chief Executive Officer

*/s/ Xavier Harland*

Xavier Harland  
Chief Financial Officer

**FORM 52-109F2  
CERTIFICATION OF INTERIM FILINGS  
FULL CERTIFICATE**

**I, Henri Harland, President and Chief Executive Officer of Acasti Pharma Inc., certify the following:**

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Acasti Pharma Inc. (the “issuer”) for the interim period ended August 31<sup>st</sup>, 2013.
2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
4. **Responsibility:** The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuers’ Annual and Interim Filings (c. V-1.1, r.27), for the issuer.
5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings.
  - (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
    - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
    - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
  - (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
- 5.1 **Control framework:** The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is the COSO (Committee of Sponsoring Organizations in the Treadway Commission) Internal Controls – Integrated Framework.
- 5.2 – N/A
- 5.3 – N/A
6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on June 1<sup>st</sup>, 2013 and ended on August 31<sup>st</sup>, 2013 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

Date: October 15<sup>th</sup>, 2013

*/s/ Henri Harland*

Henri Harland  
President and Chief Executive Officer

**FORM 52-109F2**  
**CERTIFICATION OF INTERIM FILINGS**  
**FULL CERTIFICATE**

I, **Xavier Harland**, Chief Financial Officer of **Acasti Pharma Inc.**, certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Acasti Pharma Inc. (the “issuer”) for the interim period ended August 31<sup>st</sup>, 2013.
2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
4. **Responsibility:** The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuers’ Annual and Interim Filings (c. V-1.1, r.27), for the issuer.
5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings.
  - (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
    - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
    - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
  - (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
- 5.1 **Control framework:** The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is the COSO (Committee of Sponsoring Organizations in the Treadway Commission) Internal Controls – Integrated Framework.
- 5.2 – N/A
- 5.3 – N/A
6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on June 1<sup>st</sup>, 2013 and ended on August 31<sup>st</sup>, 2013 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

Date: October 15<sup>th</sup>, 2013

/s/ *Xavier Harland*

Xavier Harland  
 Chief Financial Officer